Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.40 -0.46% 1,383.60 1,386.60 1,387.20 1,391.40 1,373.20 1,380.60 21,110,506 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 14.7 69,420

Glaxosmithkline Share Discussion Threads

Showing 19101 to 19123 of 23075 messages
Chat Pages: Latest  767  766  765  764  763  762  761  760  759  758  757  756  Older
DateSubjectAuthorDiscuss
07/2/2019
08:51
Thanks for the reply h-e. You've confirmed what was implied in my question, which is that current FCF cover is not much use as an indicator of future dividends because of the volatility arising from the one-offs that you list. With 2019 profits expected to be lower too, and the Consumer Healthcare side of the company being hived off, FCF cover in the near future is not exactly transparent anyway. I'm just happy that the 80p divi is maintained for now, and wasn't expecting any increase this year or next. Just wonder why the final results mention the metric of 1.25x to 1.5x cover at all.
broadgreen
07/2/2019
08:48
Surely not many selling 23p quarterly div ex in a couple of weeks. I would have thought get that then sell.
montyhedge
07/2/2019
07:09
Don't know this posted twice, repetition deleted
hydrogen economy
07/2/2019
07:09
Broadgreen As you say Div was very well covered by FCF in 2018 (indeed Q418 FCF at 3.3b almost covered the FY divis),but it was distorted by one offs :- -Reduction of inventory balances -favourable timing of payments for returns and rebates -reduced legal settlement costs and restructuring payments, -lower capital expenditure -increased disposals of intangible assets of £256 million But Profits expected to drop again next year and one-offs could well go the other way. The number of deals being done means lots of one-off costs so I think no certainty of a rise in 2020, we can only watch and hope.
hydrogen economy
07/2/2019
03:39
Glaxo hunts more deals to stay competitive, Walmsley says hTtps://www.telegraph.co.uk/business/2019/02/06/glaxo-hunts-deals-stay-competitive-walmsley-says/ GlaxoSmithKline strategy revamp and shingles drug help boost earnings htTps://www.ft.com/content/5eabccc2-2a01-11e9-a5ab-ff8ef2b976c7
xxxxxy
06/2/2019
17:31
Net debt has increased from 13bn to 21bn. We better start generating bigger profits.
zicopele
06/2/2019
16:55
Can’t see why any of us is not delighted at the share price movement over the last two days, except anhar, of course, to whom it does not matter!
jadeticl3
06/2/2019
16:40
You must have said the same thing now over ten times in January..why?
badtime
06/2/2019
16:10
Emma Walmsley, CEO, GSK, summarises our performance in 2018 hTTps://www.youtube.com/watch?time_continue=348&v=CLBhM5O6c0Y
wbecki
06/2/2019
16:08
Looks like another test of 1600 on the cards.
tim 3
06/2/2019
15:43
Don't worry about it,such concerns are discounted in the current rating.
steeplejack
06/2/2019
15:38
No higher dividends any time soon. Major investment in drug discovery required and debts which are extremely high.
zicopele
06/2/2019
15:32
I'm a bit puzzled by the following - maybe someone better at deciphering financial statements can shed some light: 2018 dividends cost £3935m Aim is to build Free Cash Flow/Dividend cover to 1.25x - 1.5x before raising the dividend. That implies FCF of £4918m-£5902m before divi can be increased. But 2018 FCF was £5692m. Almost at the top of the targeted cover range. Does this imply higher dividends soon, despite the forecast unchanged 80p dividend for 2019?
broadgreen
06/2/2019
15:22
GlaxoSmithKline gaining 0.3 percent to 1.527 pence after the British pharmaceutical laboratory announced Wednesday that its pre-tax profit had more than tripled in the fourth quarter. The Group also indicated that generic products of its competitors might does not affect its results of 2019 as much as some anticipated it. Jefferies, the market should appreciate the goal of the group to a drop of 5% to 9% of earnings per share at constant exchange rates this year, as many feared a double-digit decline."Current consensus lies just below the middle of the range for earnings per share, which indicates that it should evolve in a limited way", noted analysts at Jefferies
beckers2008
06/2/2019
15:19
You're made off strong stuff Monty, even my cats won't go out today. Phil, that might be a good short term move.
essentialinvestor
06/2/2019
15:10
Just back from golf, superb, 1635p here we come.
montyhedge
06/2/2019
14:48
Stock has broken through $40 in the USA,highest level in a couple of months.The USA will ultimately dictate how the stock moves.
steeplejack
06/2/2019
14:39
A quick scan of the balance sheet has two big movements - the derecognition of non-controlling interests and borrowings. Linked to the JV.
alphorn
06/2/2019
13:46
Yes, Merrill Lynch have upgraded VOD to 'buy' this morning. They reckon a one-third cut in the dividend is now priced in. Top sliced 10% off GSK a few minutes ago.
philanderer
06/2/2019
13:37
Slowly but surely a lot of the apparent high yielders are being wormed out.Jeffries thinks Vodaphone will have to cut the dividend in due course,now on a historic yield of over 9%.Thus,Glaxo forecasting a maintained dividend for 2019 puts it in the safe yield camp prospectively yielding over 5%.Makes Glaxo a very sound investment in 2019 (despite the dip in earnings this year)if you care to look longer term.
steeplejack
06/2/2019
13:15
Buy these pesky dips and pull backs Sir!
ny boy
06/2/2019
13:13
Who sold before the results ?
abdullla
06/2/2019
12:59
Yes, Anhar, as if that was the main representative news! (and its hardly 'news' - this has been heralded for over 2 years)
tradermichael
Chat Pages: Latest  767  766  765  764  763  762  761  760  759  758  757  756  Older
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201129 14:37:02